Table 1.
Relationship of MAGEC2 expression and clinicopathologic characteristics of patients with IDC
| Variables | MAGEC2/CT10 expression | ||
|---|---|---|---|
| Negative, n (%) (n = 306) | Positive, n (%) (n = 114) | P value | |
| Age at menarche | |||
| ≤14 (years) | 127 (77.4) | 37 (22.6) | 0.091 |
| >14 (years) | 179 (69.9) | 77 (30.1) | |
| Menopausal status | |||
| Premenopausal | 165 (72.1) | 64 (27.9) | 0.685 |
| Premenopausal | 141 (73.85) | 50 (26.6) | |
| Tumor size | |||
| ≤2 cm | 94 (69.1) | 42 (30.9) | 0.137 |
| 2–5 cm | 115 (71.0) | 47 (29.0) | |
| >5 cm | 97 (79.5) | 25 (20.5) | |
| Tumor grade | |||
| 1 | 90 (78.9) | 24 (21.1) | 0.014* |
| 2 | 120 (76.4) | 37 (23.6) | |
| 3 | 96 (64.4) | 53 (35.6) | |
| Lymph node stage | |||
| 1 (Negative) | 98 (78.4) | 27 (21.6) | 0.013* |
| 2 (1–3 LN involved) | 136 (75.6) | 44 (24.4) | |
| 3 (>5) | 72 (62.6) | 43 (37.4) | |
| Tumor stage | |||
| I + II | 196 (78.4) | 54 (21.6) | 0.002* |
| III + VI | 110 (64.7) | 60 (35.3) | |
| Distant metastasis | |||
| Yes | 126 (66.0) | 65 (34.0) | 0.004* |
| No | 180 (78.6) | 49 (21.4) | |
| ER | |||
| Negative | 121 (67.6) | 58 (32.4) | 0.037* |
| Positive | 185 (76.8) | 56 (23.2) | |
| PR | |||
| Negative | 152 (75.2) | 50 (24.8) | 0.289 |
| Positive | 154 (70.6) | 64 (29.4) | |
| HER2 | |||
| Negative | 161 (69.7) | 70 (30.3) | 0.107 |
| Positive | 145 (76.7) | 44 (23.3) | |
* Statistically significant (P < 0.05)